← Back to Search

Atherectomy Device

Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm for Peripheral Vascular Disease

N/A
Waitlist Available
Research Sponsored by Midwest Cardiovascular Research Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will compare the effectiveness of two treatments for complex lesions in the femoropopliteal arteries of people with claudication.

Eligible Conditions
  • Peripheral Vascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Major Adverse Events
Target Lesion Revascularization

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCBExperimental Treatment1 Intervention
Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
Group II: POBA+DCB (Ranger or IN.PACT)Active Control1 Intervention
POBA and then DCB treatment (Ranger or IN.PACT)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
2018
N/A
~50

Find a Location

Who is running the clinical trial?

Midwest Cardiovascular Research FoundationLead Sponsor
5 Previous Clinical Trials
277 Total Patients Enrolled
Nicolas Shammas, MD, Research DirectorStudy DirectorMCRF

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Apr 2025